Page 237 - Read Online

to 2 patients in order to overcome the ADR. One patient REFERENCES
ceased and continued therapy. Further recommendations
were made to overcome the ADR but we have not included 1. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao
that recommendation in our study. H. Sorafenib improves the survival of patients with advanced
hepatocellular carcinoma: a meta-analysis of randomized trials.
Anticancer Drugs 2010;21:326-32.
[12]
Llovet et al. conducted the sorafenib Hepatocellular 2. Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A,
Carcinoma Assessment Randomized Protocol study Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM,
shows that the adverse event is more common in Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR,
sorafenib group compared to the placebo group, were Sharma H, Thandassery RB; The INASL Task-Force on Hepatocellular
diarrhoea (n = 39), fatigue (n = 22), hand-foot syndrome Carcinoma. The Indian National Association for Study of the Liver
(INASL) Consensus on Prevention, Diagnosis and Management of
(HFS) (n = 21). Sorafenib associated adverse event led Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin
to dose reductions and interruptions in a subgroup of Exp Hepatol 2014;4:S3-26.
patients. The study enrolled 602 patients; this was phase 3. Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B,
3 double blind placebo controlled trial. Berger BD, O’Connor JK, Goldstein RM. Hepatocellular carcinoma:
management of an increasingly common problem. Proc (Bayl Univ
Med Cent) 2008;21:266-80.
Expect from the usual adverse drug reactions sorafenib was 4. Hu H, Duan Z, Long X, Hertzanu Y, Shi H, Liu S, Yang Z. Sorafenib
found as a good choice for treating patients with advanced combined with transarterial chemoembolization versus transarterial
HCC. chemoembolization alone for advanced-stage hepatocellular carcinoma:
a propensity score matching study. PLoS One 2014;9:e96620.
5. Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K,
Limitations, all the data were collected retrospectively Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai
except survival rate, no computed tomography scan details T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M,
available so that it was unable to assess the tumour size, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M. Efficacy,
less population was involved there were only 41 samples safety, and survival factors for sorafenib treatment in Japanese patients
were available, no proper contact details of the patients 6. with advanced hepatocellular carcinoma. Oncology 2013;84:108-14.
Xie B, Wang DH, Spechler SJ. Sorafenib for the treatment of
were available because of that some patients survival days hepatocellular carcinoma: a systematic review. Dig Dis Sci
were excluded, lack of follow-up of some patients after 2012;57:1122-9.
treatment. 7. Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship
of ethinity and overall survival in patients treated with sorafenib
In conclusion, sorafenib improves the overall survival of for advanced hepatocellular carcinoma. J Gastrointest Oncol
2014;5:259-64.
the patients with advanced HCC in Indian population. 8. Zheng SZ, Liu DJ, Sun P, Yu GS, Xu YT, Gong W, Liu J. Feasibility
The median overall survival was found to be 114 days and safety of sorafenib treatment in hepatocellular carcinoma patients
(3.8 months). It is a safe and effective treatment for with spontaneous rupture. World J Gastroenterol 2014;20:16275-81.
patients with advanced HCC in Indian population. The 9. Abdel-Rahman O, Abdelwahab M, Shaker M, Abdelwahab S,
survival of patients was found to depend on the liver Elbassiony M, Ellithy M. Sorafenib for Egyptian patients with
advanced hepatocellular carcinoma; single centre experience. J Egypt
function. The adverse effect was found to be almost same Natl Canc Inst 2014;26:9-13.
as other countries apart from that we found insomnia 10. Køstner AH, Sorensen M, Olesen RK, Grønbæk H, Lassen U, Ladekarl
in our population. The adverse effects include fatigue, M. Sorafenib in advanced hepatocellular carcinoma: a nationwide
diarrhoea, HFS, hyperbilirubinemia, nausea and vomiting. retrospective study of efficacy and tolerability. Scientific World Journal
2013;2013:931- 72.
Finally, we conclude that sorafenib is best oral systemic 11. Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang
therapy for advanced HCC in Indian population. XJ, Zou X, Sun L, Zhang ZC. Sorafenib in liver function impaired
advanced hepatocellular carcinoma. Chin Med Sci J 2014;29:7-14.
Financial support and sponsorship 12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de
Nil. Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta
C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath
I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D,
Conflicts of interest Bruix J; SHARP Investigators Study Group. Sorafenib in advanced
There are no conflicts of interest. hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

228 Hepatoma Research | Volume 2 | August 5, 2016